PsyProtix

PsyProtix was a precision psychiatry biotechnology company launched in 2021 by atai Life Sciences together with Chymia, a Duke University spinout. The company was created to develop more personalized therapeutics for treatment-resistant depression and related mental health conditions by using metabolomic and precision-medicine approaches to identify patient subtypes and tailor treatment. Publicly available materials describe PsyProtix as focusing on metabolomic mechanisms underlying depressive symptoms rather than on a disclosed clinical-stage asset portfolio. The company appears to have remained at an early preclinical/platform stage, and later third-party company databases indicated that it is no longer active. PsyProtix was part of atai's broader network of platform companies targeting innovation in mental health therapeutics.